MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Cerebrospinal fluid measured α-synuclein is related to metabolite profile in the serum and CSF

    K. Paul, D. Jones, B. Ritz (Los Angeles, USA)

    Objective: Determine metabolites associated with cerebrospinal fluid (CSF) measured α-synuclein (α-syn) using untargeted metabolomics measured in the serum and CSF. Background: Several large studies have…
  • 2025 International Congress

    Continuous subcutaneous foslevodopa/foscarbidopa infusion therapy leads to a sustained reduction in dyskinesias in Parkinson’s disease

    M. Georgiades, D. Tsui, X. Chen, S. Bray, J. Qiu, S. Waller, L. Williams, S. Dal, T. Ong, A. Martin, H. Morales-Briceno, V. Fung (Sydney, Australia)

    Objective: To assess the longitudinal effect of continuous subcutaneous foslevodopa/foscarbidopa infusion therapy on dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) total score…
  • 2025 International Congress

    Patient engagement in Parkinson’s research: Exploring stakeholder perspectives

    J. Bek, N. Simonian, C. Rattan, A. Asis (Dublin, Ireland)

    Objective: The aim of this project was to explore patient engagement in Parkinson’s research in Canada from the perspectives of different stakeholders, and to identify…
  • 2025 International Congress

    The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease

    I. Malaty, P. Odin, D. Kern, L. Bergmann, M. Shah, R. Gupta, A. Antonini, K. Chaudhuri (Gainesvile, USA)

    Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…
  • 2025 International Congress

    Three-Year Single-Center Experience with Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease

    J. Szász, V. Constantin, K. Orbán-Kis, S. Bataga, R. Neagoe, M. Ciorba, K. Kelemen, I. Mihály, S. Szatmári (TARGU MURES, Romania)

    Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in advanced Parkinson’s Disease (APD). Background: LECIG infusion has been available in Romania since 2021.…
  • 2025 International Congress

    Botulinium toxin in treatment of Parkinsonism

    A. Wankar (Nagpur, India)

    Objective: This review discusses the use of BT in various motor and non-motor symptoms of Parkinsonism. This review discusses the use of BT in various…
  • 2025 International Congress

    Inpatient Multimodal Care Improves Parkinsonian Symptoms Regardless Of Race Or Ethnicity

    N. Elayan, L. Rubin, M. Mccrossin, A. Di Rocco, M. Ghilardi (New York, USA)

    Objective: To verify demographic characteristics of patients with Parkinson’s disease (PD) completing a two-week inpatient multimodal intensive neurorehabilitation and care (iMINC) program and whether iMINC…
  • 2025 International Congress

    Zonisamide for Motor Symptoms and OFF-Time Reduction in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the efficacy and safety of zonisamide as an adjunct therapy for improving motor function and reducing OFF-time in patients with Parkinson’s disease…
  • 2025 International Congress

    COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Six Months Analysis Of REONPARK Study

    L. López-Manzanares, M. Cerdán Sánchez, B. Solano Vila, J. García-Caldentey, A. Rodríguez-Sanz, J. Olivares Romero, H. Brigas, D. Martins, J. Blanco Ameijeiras, M. Rodríguez-de Miguel (Madrid, Spain)

    Objective: The REONPARK study aims to evaluate COMT inhibitors (COMTi) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s disease (PD)…
  • 2025 International Congress

    Investigation of cortex – basal ganglia pathways with cortical stimulation and subthalamic evoked responses in patients with Parkinson’s disease

    J-C. Beyer, A. Cavallo, R M. Köhler, J. Vanhoecke, G-H. Schneider, A A. Kühn, W-J. Neumann (Berlin, Germany)

    Objective: To investigate the electrophysiological interplay between the human cortex and the subthalamic nucleus (STN) by comparing STN responses to direct cortical electrical stimulation and…
  • « Previous Page
  • 1
  • …
  • 314
  • 315
  • 316
  • 317
  • 318
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley